A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

• Autors principals: Josefina Cadorna Carlos (Autor), Birkneh Tilahun Tadesse (Autor), Charissa Borja-Tabora (Autor), Edison Alberto (Autor), Michelle C. Ylade (Autor), Arijit Sil (Autor), Deok Ryun Kim (Autor), Hyeon Seon Ahn (Autor), Jae Seung Yang (Autor), Ji Yeon Lee (Autor), Min Soo Kim (Autor), Jiwook Park (Autor), Soo-Young Kwon (Autor), Hun Kim (Autor), Seon-Young Yang (Autor), Ji-hwa Ryu (Autor), Hokeun Park (Autor), Jong-hoon Shin (Autor), Yoonyeong Lee (Autor), Jerome H. Kim (Autor), Zenaida Reynoso Mojares (Autor), T. Anh Wartel (Autor), Sushant Sahastrabuddhe (Autor)
• Format: Llibre
• Publicat: Elsevier, 2022-07-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Summary: Trial Design: Phase 3, randomized, controlled, multicenter, equivalence trial. Methods: Recruitment of participants occurred between 04Februray2020 and 15July2020 at four centers in the Philippines: University of the East - Ramon Magsaysay Memorial Medical Center Inc., Quezon City; Universi...